Patients' immune system may influence effectiveness of cancer immunotherapy

April 2, 2017
T cell
Scanning electron micrograph of human T lymphocyte or T cell. Credit: NIAID/NIH

Higher or lower levels of certain immune cells in cancer patients may be associated with how well they respond to immunotherapy, according to preliminary results of a study conducted by researchers at the University of Pittsburgh Cancer Institute (UPCI).

The findings will be presented today at the American Association of Cancer Research (AACR) Annual Meeting in Washington, D.C., by Robert Ferris, M.D., Ph.D., UPMC Endowed Professor, chief of the Division of Head and Neck Surgery, and co-leader of the Cancer Immunology Program at UPCI.

The research was an extension of the recently completed CheckMate 141 Phase III clinical trial co-chaired by Dr. Ferris, which showed that the nivolumab significantly increases survival and causes fewer adverse side effects in patients with recurrent head and neck cancer.

However, the treatment was not equally effective in all the patients so Dr. Ferris and his team aimed to find out whether differences in the patients' immune system profiles could be associated with better response to immunotherapy.

The researchers found that higher levels of tumor-associated (TAICs) expressing the PD-L1 protein were associated with longer overall survival and greater likelihood of response to the drug nivolumab. TAICs are immune that have infiltrated the tumor and are thought to play an important role in tumor growth.

In blood samples taken prior to the start of immunotherapy, the researchers also found that patients with of circulating CD8, or cytotoxic, T cells—also known as killer T cells—and lower levels of regulatory T cells were associated with better response to treatment.

"Our study shows that immune cells in the microenvironment around the tumor could play a critical role in how patients respond to immunotherapy. By determining the nature of these cells and how they are affected by treatments, we may be able to significantly improve the effectiveness of current therapies and help a greater number of ," said Dr. Ferris.

Explore further: Immunotherapy prolongs life, reduces side effects and improves quality of life

More information: This study was funded by UPCI and Bristol-Myers Squibb.

Related Stories

Immunotherapy prolongs life, reduces side effects and improves quality of life

October 11, 2016
The immunotherapy nivolumab significantly increases survival and causes fewer adverse side-effects in patients with recurrent head and neck cancer, according to a randomized trial co-led by investigators at the University ...

Researchers use new computational method to define immune cell interactions

March 15, 2017
Immunotherapy, harnessing a patient's immune system to help fight cancer, has shown much promise as a potential cancer treatment. In a newly published study, a research team at Dartmouth-Hitchcock's Norris Cotton Cancer Center ...

Immunotherapy improves survival, quality of life in rapidly progressing head and neck cancer

June 6, 2016
Immunotherapy doubles overall survival and improves quality of life, with fewer side effects, in a treatment-resistant and rapidly progressing form of head and neck carcinoma, reports a large, randomized international trial ...

Cancers evade immunotherapy by 'discarding the evidence' of tumor-specific mutations

January 5, 2017
Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination ...

Immunotherapy drug gives non-small-cell lung cancer patients extra four months of life

December 13, 2016
Patients with advanced non-small-cell lung cancer survive four months longer with fewer side effects on an immunotherapy drug called atezolizumab compared to chemotherapy, according to a phase 3 clinical trial published in ...

'Starving' immune cell discovery points to cancer immunotherapy-boosting strategies

July 29, 2016
The microenvironment that supports a cancerous tumor also starves the immune cells that the body sends in to destroy the cancer, University of Pittsburgh Cancer Institute (UPCI) scientists revealed in a discovery that holds ...

Recommended for you

New strategy for unleashing cancer-fighting power of p53 gene

December 13, 2017
Tumor protein p53 is one of the most critical determinants of the fate of cancer cells, as it can determine whether a cell lives or dies in response to stress. In a new study published today in the journal Nature Communications, ...

Researchers develop test that can diagnose two cancer types

December 12, 2017
A blood test using infrared spectroscopy can be used to diagnose two types of cancer, lymphoma and melanoma, according to a study led by Georgia State University.

Cancer-causing mutation suppresses immune system around tumours

December 12, 2017
Mutations in 'Ras' genes, which drive 25% of human cancers by causing tumour cells to grow, multiply and spread, can also protect cancer cells from the immune system, finds a new study from the Francis Crick Institute and ...

Atoh1, a potential Achilles' heel of Sonic Hedgehog medulloblastoma

December 12, 2017
Medulloblastoma is the most common type of solid brain tumor in children. Current treatments offer limited success and may leave patients with severe neurological side effects, including psychiatric disorders, growth retardation ...

Drug suppresses spread of breast cancer caused by stem-like cells

December 12, 2017
Rare stem-like tumor cells play a critical role in the spread of breast cancer, but a vulnerability in the pathway that powers them offers a strategy to target these cells using existing drugs before metastatic disease occurs, ...

MRI scans predict patients' ability to fight the spread of cancer

December 12, 2017
A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.